Factors Associated With Decision Making In the Second-Line Treatment of Patients With Advanced/Metastatic Gastrointestinal Cancers
Podcast 3: Advances in anti-angiogenic treatment for GEJ cancers with clinical trials
Post-Test/Evaluation

Questions marked with a * are required

18%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Edith is a 71 year-old woman with HER2- gastric cancer and diffuse nodal metastases whose cancer has progressed despite being on FOLFOX/nivolumab therapy. She is interested in enrolling in a clinical trial. What factors should she consider before pursuing further treatment?

A. Treatment toxicities

B. Her ultimate goals, including quality of life

C. Treatment burden factors like cost, transportation, frequency of appointment, etc

D. All of the above

Edith is interested in a trial looking at combining anti-VEGF treatment options. What information can you give her regarding anti-VEGF use in second-line therapy?

A. Ramucirumab monotherapy has not shown to be effective in HER2- cancers

B. The data for the best responses so far are with combining chemotherapy and anti-VEGF therapy, such as with paclitaxel + ramucirumab or FOLFIRI + ramucirumab

C. There are no clinical trials looking at combining immunotherapy strategies with anti-VEGF-targeted therapies

D. Severe hypertension does not require stopping ramucirumab treatment